These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 1821700)
1. Interest of a loading dose of milnacipran in endogenous depressive inpatients. Comparison with the standard regimen and with fluvoxamine. Ansseau M; von Frenckell R; Gérard MA; Mertens C; De Wilde J; Botte L; Devoitille JM; Evrard JL; De Nayer A; Darimont P Eur Neuropsychopharmacol; 1991 May; 1(2):113-21. PubMed ID: 1821700 [TBL] [Abstract][Full Text] [Related]
2. Controlled comparison of two doses of milnacipran (F 2207) and amitriptyline in major depressive inpatients. Ansseau M; von Frenckell R; Mertens C; de Wilde J; Botte L; Devoitille JM; Evrard JL; De Nayer A; Darimont P; Dejaiffe G Psychopharmacology (Berl); 1989; 98(2):163-8. PubMed ID: 2569214 [TBL] [Abstract][Full Text] [Related]
3. Controlled comparison of milnacipran and fluoxetine in major depression. Ansseau M; Papart P; Troisfontaines B; Bartholomé F; Bataille M; Charles G; Schittecatte M; Darimont P; Devoitille JM; De Wilde J Psychopharmacology (Berl); 1994 Feb; 114(1):131-7. PubMed ID: 7846195 [TBL] [Abstract][Full Text] [Related]
4. Long-term efficacy and safety of milnacipran compared to clomipramine in patients with major depression. Leinonen E; Lepola U; Koponen H; Mehtonen OP; Rimon R Acta Psychiatr Scand; 1997 Dec; 96(6):497-504. PubMed ID: 9421348 [TBL] [Abstract][Full Text] [Related]
5. Antidepressant efficacy and tolerability of milnacipran, a dual serotonin and noradrenaline reuptake inhibitor: a comparison with fluvoxamine. Clerc G; Int Clin Psychopharmacol; 2001 May; 16(3):145-51. PubMed ID: 11354236 [TBL] [Abstract][Full Text] [Related]
6. Milnacipran and pindolol: a randomized trial of reduction of antidepressant latency. Isaac MT; Isaac MB; Gallo F; Tournoux A Hum Psychopharmacol; 2003 Dec; 18(8):595-601. PubMed ID: 14696018 [TBL] [Abstract][Full Text] [Related]
7. Differential effects of milnacipran and fluvoxamine, especially in patients with severe depression and agitated depression: a case-control study. Fukuchi T; Kanemoto K Int Clin Psychopharmacol; 2002 Mar; 17(2):53-8. PubMed ID: 11890186 [TBL] [Abstract][Full Text] [Related]
8. A double-blind comparison of the efficacy and safety of milnacipran and fluoxetine in depressed inpatients. Guelfi JD; Ansseau M; Corruble E; Samuelian JC; Tonelli I; Tournoux A; Plétan Y Int Clin Psychopharmacol; 1998 May; 13(3):121-8. PubMed ID: 9690979 [TBL] [Abstract][Full Text] [Related]
9. Gender differences in the clinical effects of fluvoxamine and milnacipran in Japanese major depressive patients. Naito S; Sato K; Yoshida K; Higuchi H; Takahashi H; Kamata M; Ito K; Ohkubo T; Shimizu T Psychiatry Clin Neurosci; 2007 Aug; 61(4):421-7. PubMed ID: 17610668 [TBL] [Abstract][Full Text] [Related]
10. [Prediction of antidepressant response to milnacipran and fluvoxamine using pharmacogenetical methods]. Higuchi H Nihon Shinkei Seishin Yakurigaku Zasshi; 2010 Apr; 30(2):71-6. PubMed ID: 20491280 [TBL] [Abstract][Full Text] [Related]
11. The G196A polymorphism of the brain-derived neurotrophic factor gene and the antidepressant effect of milnacipran and fluvoxamine. Yoshida K; Higuchi H; Kamata M; Takahashi H; Inoue K; Suzuki T; Itoh K; Ozaki N J Psychopharmacol; 2007 Aug; 21(6):650-6. PubMed ID: 17092970 [TBL] [Abstract][Full Text] [Related]
12. Bcl1 polymorphism of the glucocorticoid receptor gene and treatment response to milnacipran and fluvoxamine in Japanese patients with depression. Takahashi H; Yoshida K; Higuchi H; Kamata M; Inoue K; Suzuki T; Ishigooka J Neuropsychobiology; 2014; 70(3):173-80. PubMed ID: 25358426 [TBL] [Abstract][Full Text] [Related]
13. A double-blind six months comparative study of milnacipran and clomipramine in major depressive disorder. Steen A; Den Boer JA Int Clin Psychopharmacol; 1997 Sep; 12(5):269-81. PubMed ID: 9466161 [TBL] [Abstract][Full Text] [Related]
14. Controlled comparison of two different doses of milnacipran in major depressive outpatients. Kanemoto K; Matsubara M; Yamashita K; Tarao Y; Inada E; Sekine T Int Clin Psychopharmacol; 2004 Nov; 19(6):343-6. PubMed ID: 15486520 [TBL] [Abstract][Full Text] [Related]
15. A randomised, double-blind comparison of milnacipran and imipramine in the treatment of depression. Van Amerongen AP; Ferrey G; Tournoux A J Affect Disord; 2002 Oct; 72(1):21-31. PubMed ID: 12204314 [TBL] [Abstract][Full Text] [Related]
17. Comparative studies with milnacipran and tricyclic antidepressants in the treatment of patients with major depression: a summary of clinical trial results. Kasper S; Pletan Y; Solles A; Tournoux A Int Clin Psychopharmacol; 1996 Sep; 11 Suppl 4():35-9. PubMed ID: 8923125 [TBL] [Abstract][Full Text] [Related]
18. Differential period of onset of action of fluvoxamine, paroxetine and milnacipran for depression. Morishita S; Arita S Hum Psychopharmacol; 2003 Aug; 18(6):479-82. PubMed ID: 12923828 [TBL] [Abstract][Full Text] [Related]
19. Psychiatric comorbidities and use of milnacipran in patients with chronic dizziness. Horii A; Imai T; Kitahara T; Uno A; Morita Y; Takahashi K; Inohara H J Vestib Res; 2016 Jul; 26(3):335-40. PubMed ID: 27392838 [TBL] [Abstract][Full Text] [Related]
20. Subjective and polysomnographic effects of milnacipran on sleep in depressed patients. Lemoine P; Faivre T Hum Psychopharmacol; 2004 Jul; 19(5):299-303. PubMed ID: 15252822 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]